What We Do
Medical Need
Improved Time-to-Market
Initial Disease Focus
Score Pharma is developing new, more potent antibody therapeutics by transforming existing clinically proven antibody therapeutics for an improved patient response.
Initial Disease Focus
Improved Time-to-Market
Initial Disease Focus
Our team is prioritizing cancer therapies such as non-Hodgkin lymphoma (NHL),
Chronic Lymphocytic Leukemia (CLL), and HER2-positive breast cancer.
Improved Time-to-Market
Improved Time-to-Market
Improved Time-to-Market
By enhancing existing technologies with a patent-pending improvement process, we expect better therapies with a higher probability of clinical and regulatory success.